Sesen Bio, Inc. (SESN) Social Stream



Sesen Bio, Inc. (SESN): $0.80

-0.01 (-1.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SESN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Featured Post From StockTwits About SESN

$SESN The trial included 133 patients, who were places into 1 of 3 cohorts: patients with carcinoma in situ with or without papillary disease that was refractory or the patient had recurred within 6 months of adequate BCG treatment; patients with carcinoma in situ with or without papillary disease that recurred between 6 and 11 months of BCG treatment; and patients with papillary disease only that recurred within 6 months of BCG treatment.

The study design consisted of a screening period, a 12-week induction phase, and a maintenance phase of up to 21 cycles of treatment, for a total of 104 weeks of treatment. Vicineum at 30 mg in 50 mL of saline was instilled into the bladder 2 hours on a schedule of 2 times per week for 6 weeks in the induction phase, followed by weekly for 6 weeks followed by every 2 weeks for up to 2 years as the maintenance phase. The coprimary end points of the trial are CR rate and the duration of response (DOR) in the first cohort.
PuraVida62, published August 14, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5416 seconds.